shares surged Friday after the company said it had received a U.S. patent for technology that detects genetic variants.

Shares in the San Diego-based company rose 69 cents, or 11%, to $6.97 in preopen trading.

The patent is a continuation of patents issued to Nanogen, that covers methods and apparatus that are particularly useful for detecting varying lengths of genetic variants.

"We continue our strategy of building Nanogen's intellectual property position in order to preserve the value of our novel technologies and their potential applications," the company said in a statement.